152 filings
PRE 14A
SCPH
scPharmaceuticals Inc
12 Apr 24
Preliminary proxy
4:14pm
EFFECT
SCPH
scPharmaceuticals Inc
25 Mar 24
Notice of effectiveness
12:15am
424B5
SCPH
scPharmaceuticals Inc
22 Mar 24
Prospectus supplement for primary offering
4:48pm
S-8
SCPH
scPharmaceuticals Inc
13 Mar 24
Registration of securities for employees
4:58pm
S-3
SCPH
scPharmaceuticals Inc
Shelf registration
13 Mar 24
4:49pm
8-K
8p92adfm
13 Mar 24
Generated full-year net FUROSCIX® revenue of $13.6 million, at the upper end of the range provided in January
4:08pm
8-K
y6f8f
4 Jan 24
Gross-to-net (GTN) discount of approximately 18% from launch through the end of Q4
5:30pm
8-K
4amazfcq0y bacoqws
8 Nov 23
Results of Operations and Financial Condition
4:05pm
8-K
0ouer
20 Sep 23
Entry into a Material Definitive Agreement
4:10pm
8-K
15c4e
10 Aug 23
Results of Operations and Financial Condition
4:05pm
8-K
tq1g4x42oghxfpgap
8 Jun 23
Submission of Matters to a Vote of Security Holders
4:11pm
8-K
nsvw5oby9vxps0jh
7 Jun 23
Other Events
7:00am
8-K
k6ju ow366j9u
10 May 23
Announced launch and commercial availability of FUROSCIX® on February 20th
4:08pm
DEFA14A
t1blvv7cjwft
27 Apr 23
Additional proxy soliciting materials
4:20pm
S-8
q6fhznk6r by40z
22 Mar 23
Registration of securities for employees
5:18pm